Study Examines Multiple PARP Inhibitors
A featured poster session at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting detailed the results of a study comparing the efficacy and tolerability of PARP inhibitors as maintenance treatment in BRCA-mutated platinum-sensitive relapsed ovarian cancer.
Prior research has demonstrated the ability of PARP inhibitor maintenance therapy to significantly increasing progression-free survival (PFS) in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer. No head-to-head comparative studies of PARP inhibitors have been conducted in patients with platinum-sensitive ovarian cancer.
Alfred W Sackeyfio, director of health economics and payer analytics, AstraZeneca (Cambridge, United Kingdom), and colleagues conducted a mixed-treatment comparison of Lynparza (olaparib; Astrazenca), Zejula (niraparib; Tesaro), and Rubraca (rucaparib; Clovis) to evaluate comparative efficacy and tolerability in patients with BRCA-mutated disease. Researchers utilized Bayesian mixed-treatment comparison efficacy analyses to evaluate investigator and independent review committee PFS hazard ratios, using data from multiple studies. Safety analyses were utilized to assess odds ratios of grade 3/4 adverse events, treatment interruption, and dose reductions due to adverse events.
Researchers observed no efficacy differences between the PARP inhibitors.
Researchers presented the data from three PARP inhibitor phase 3 studies in platinum-sensitive relapsed ovarian cancer: SOLO2 (Lynparza 300 mg tablets), NOVA (Zejula 300 mg capsules), and ARIEL3 (Rubraca 600 mg tablets).
After analyzing data for median PFS, grade 3/4 adverse events, treatment interruption, and dose reduction, researchers found that Lynparza showed a significant reduction in odds of grade 3/4 adverse events and treatment interruption compared with Zejula and Rubraca. Additionally, data showed that Lynparza was associated with a significant reduction in odds of dose reduction compared with Zejula.
Researchers concluded that while no significant efficacy difference exists between PARP inhibitors in the maintenance setting following response to chemotherapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer, Lynparza demonstrates superior tolerability compared with Zejula and Rubraca.
—Zachary Bessette
